Showing results (251-260 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|October 1, 2022
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life historyAngelo Avogaro, Saula Vigili de Kreutzenberg, Mario Luca Morieri, et al.
The Lancet. Diabetes & Endocrinology|August 16, 2014
Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial
The Lancet. Diabetes & Endocrinology|May 6, 2014
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trialAnthony H Barnett, Ambrish Mithal, Jenny Manassie, et al.
The Lancet. Diabetes & Endocrinology|June 24, 2026
Whole-population trends in obesity across dimensions of inequality in England, 2019-25: a retrospective, longitudinal cohort study of 54 million adultsRobert A Fletcher, Nathalie Conrad, Patrick Rockenschaub, et al.
The Lancet. Diabetes & Endocrinology|June 26, 2026
Intermittent fasting to treat diabetes: time to update clinical practice guidelinesKrista A Varady, Lisa S Chow, Courtney M Peterson
The Lancet. Diabetes & Endocrinology|September 7, 2026
Hypoparathyroidism: translating science from the laboratory to the clinicMaria Luisa Brandi, Hajar AbuAlrob, Wenhan Chang, et al.
The Lancet. Diabetes & Endocrinology|July 5, 2022
Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort studyCarmen Piernas, Martina Patone, Nerys M Astbury, et al.
The Lancet. Diabetes & Endocrinology|October 8, 2020
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trialAhmad Al-Mrabeh, Kieren G Hollingsworth, James A M Shaw, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
The Lancet. Diabetes & Endocrinology|January 9, 2023
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trialElisabeth R Mathiesen, Amra Ciric Alibegovic, Rosa Corcoy, et al.
Pageof 93